{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:35:15Z","timestamp":1778715315238,"version":"3.51.4"},"reference-count":64,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,2,13]],"date-time":"2014-02-13T00:00:00Z","timestamp":1392249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Rep Immunol"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:p>Among women, human immunodeficiency virus type 1 (<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101) infection is most prevalent in those of reproductive age. These women are also at risk of unintended or mistimed pregnancies. Hormonal contraceptives (<jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content>s) are one of the most commonly used methods of family planning worldwide. Therefore, concurrent use of <jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content> among women on antiretroviral medications (<jats:styled-content style=\"fixed-case\">ARV<\/jats:styled-content>s) is increasingly common. <jats:styled-content style=\"fixed-case\">ARV<\/jats:styled-content>s are being investigated and have been approved for pre\u2010exposure prophylaxis (<jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>r<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content>), and therefore, drug\u2013drug interactions must also be considered in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101\u2010negative women who want to prevent both unintended pregnancy and <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101 infection. This article will review four main interactions: (i) the effect of <jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content>s on <jats:styled-content style=\"fixed-case\">ARV<\/jats:styled-content> pharmacokinetics (<jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>) and pharmacodynamics (<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>) during therapy, (ii) the effect of <jats:styled-content style=\"fixed-case\">ARV<\/jats:styled-content>s on <jats:styled-content style=\"fixed-case\">HC PK<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>, (iii) the role of drug transporters on drug\u2013drug interactions, and (iv) ongoing research into the effect of <jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content>s on pre\u2010exposure prophylaxis <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/aji.12210","type":"journal-article","created":{"date-parts":[[2014,2,13]],"date-time":"2014-02-13T10:17:41Z","timestamp":1392286661000},"page":"523-530","source":"Crossref","is-referenced-by-count":25,"title":["Effects of Hormonal Contraception on Antiretroviral Drug Metabolism, Pharmacokinetics and Pharmacodynamics"],"prefix":"10.1111","volume":"71","author":[{"given":"Andrea R.","family":"Thurman","sequence":"first","affiliation":[{"name":"CONRAD Department of Obstetrics and Gynecology Eastern Virginia Medical School Norfolk VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Anderson","sequence":"additional","affiliation":[{"name":"CONRAD Department of Obstetrics and Gynecology Eastern Virginia Medical School Norfolk VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo F.","family":"Doncel","sequence":"additional","affiliation":[{"name":"CONRAD Department of Obstetrics and Gynecology Eastern Virginia Medical School Norfolk VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,2,13]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"UNAIDS:Report on the Global AIDS Epidemic 2012."},{"key":"e_1_2_10_3_1","volume-title":"Pre\u2010Exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir\/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003)","author":"Marrazzo J","year":"2013"},{"key":"e_1_2_10_4_1","unstructured":"van der LindeI:HIV\/AIDS in South Africa: At last the glass if half full. 6th SA AIDS Conference. Durban South Africa 2013."},{"key":"e_1_2_10_5_1","unstructured":"Maternal Mortality in 2005 2005. (Accessed 07\/15\/2010 athttp:\/\/whqlibdoc.who.int\/publications\/2007\/9789241596213_eng.pdf)."},{"key":"e_1_2_10_6_1","volume-title":"Abortion Worldwide: A Decade of Uneven Progress","author":"Singh S","year":"2009"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1728-4465.2010.00250.x"},{"key":"e_1_2_10_8_1","unstructured":"World Contraceptive Use 2011 2011. (Accessed 7\/15\/2011 athttp:\/\/www.un.org\/esa\/population\/publications\/wcu2010\/Data\/UNPD_WCU_2010_Contraceptive_prevalence_method.xls)."},{"key":"e_1_2_10_9_1","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","author":"Karim QA","year":"2010","journal-title":"Science"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000219777.04927.50"},{"key":"e_1_2_10_11_1","first-page":"3297","article-title":"Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate","volume":"6","author":"Kobayashi K","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.05.011"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(90)90431-P"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1725"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/890160"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1724"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200606000-00055"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2011.48"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2013.0032"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.612"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.01.003"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078814"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069854"},{"key":"e_1_2_10_24_1","unstructured":"AIDS Info:Guidelines for the Use of Antiretroviral Agents in HIV\u20101\u2010Infected Adults and Adolescents. What to Start: Initial Combination Regimens for the Antiretroviral\u2010Naive Patient 2013.http:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv-guidelines\/11\/what-to-start."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.8.924"},{"key":"e_1_2_10_26_1","unstructured":"WHO:World Health Organization List of Essential Medicines 18th List April 2013 2013.http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/18th_EML_Final_web_8Jul13.pdf."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000244202.18629.36"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350801300415","article-title":"Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low\u2010dose ritonavir in healthy women","volume":"13","author":"Sekar VJ","year":"2008","journal-title":"Antivir Ther"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2003.01983.x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100040"},{"key":"e_1_2_10_31_1","unstructured":"World Health Organization:Medical Eligibility Criteria for Contraceptive Use 2010 2010."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200204150-00007"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2009.01.009"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi116"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.16.1.18448"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.09.002"},{"key":"e_1_2_10_37_1","unstructured":"Food and Drug Administration:FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection 2012."},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_2_10_40_1","volume-title":"The Injectable Contraceptive Depo\u2010Provera Does Not Reduce the Prophylactic Efficacy of Truvada in Pigtail Macaques","author":"Radzio J","year":"2013"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835ad539"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.olq.0000194602.01058.e1"},{"key":"e_1_2_10_43_1","first-page":"1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2010","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70120-1"},{"key":"e_1_2_10_45_1","first-page":"19","article-title":"Oral contraceptives: mechanism of action, dosing, safety, and efficacy","volume":"81","author":"Sondheimer SJ","year":"2008","journal-title":"Cutis"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000260956.61835.6d"},{"key":"e_1_2_10_47_1","first-page":"544","article-title":"Oral contraceptives and the risk of DVT","volume":"240","author":"Piegsa K","year":"1996","journal-title":"Practitioner"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91926-0"},{"key":"e_1_2_10_49_1","unstructured":"GlaxoSmithKline:Study APV10020. A Phase I open\u2010label two period single\u2010sequence drug\u2010drug interaction study comparing steady\u2010state plasma ethinyl estradiol and norethisterone pharmacokinetics following administration of brevinor for 21\u00a0days with and without fosamprenavir 700\u00a0mg twice daily (BID) and ritonavir 100\u00a0mg BID for 21\u00a0days in healthy adult female subjects 2009."},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.01.025"},{"key":"e_1_2_10_51_1","first-page":"525","article-title":"Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice","volume":"48","author":"Henzl MR","year":"2003","journal-title":"J Reprod Med"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181eb5ff5"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2007.10.002"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/137192"},{"key":"e_1_2_10_55_1","unstructured":"Bristol Meyers Squibb:Sustiva Prescribing Information 2010.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020972s033 021360s021lbl.pdf."},{"key":"e_1_2_10_56_1","unstructured":"The Antiviral Pregnancy Registry:The Antiretroviral Pregnancy Registry 2012.apregistry.com."},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.09.005"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1783\/147118907782101724"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1783\/147118910791749164"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2009.009469"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.2307\/2991537"},{"key":"e_1_2_10_62_1","first-page":"CD003550","article-title":"Non\u2010latex versus latex male condoms for contraception","author":"Gallo MF","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199804010-00006"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199107000-00010"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000159671.25950.74"}],"container-title":["American Journal of Reproductive Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faji.12210","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aji.12210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T07:18:52Z","timestamp":1694503132000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aji.12210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,13]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1111\/aji.12210"],"URL":"https:\/\/doi.org\/10.1111\/aji.12210","archive":["Portico"],"relation":{},"ISSN":["1046-7408","1600-0897"],"issn-type":[{"value":"1046-7408","type":"print"},{"value":"1600-0897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,13]]}}}